tiprankstipranks
Trending News
More News >
Kobayashi Pharmaceutical Co (JP:4967)
:4967
Advertisement

Kobayashi Pharmaceutical Co (4967) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4967

Kobayashi Pharmaceutical Co

(OTC:4967)

Rating:61Neutral
Price Target:
¥5,606.00
▲(4.82%Upside)
Kobayashi Pharmaceutical's strong balance sheet and low leverage are positive, but the negative revenue growth and profitability pressures weigh on the financial performance. Technical indicators are neutral, and the stock's valuation suggests it may be overvalued, resulting in a moderate overall stock score.

Kobayashi Pharmaceutical Co (4967) vs. iShares MSCI Japan ETF (EWJ)

Kobayashi Pharmaceutical Co Business Overview & Revenue Model

Company DescriptionKobayashi Pharmaceutical Co., Ltd. is a Japanese company that operates primarily in the pharmaceutical industry. It engages in the development, manufacture, and sale of consumer healthcare products, including over-the-counter (OTC) medications, household goods, and personal care products. The company's wide range of products includes remedies for common ailments, health supplements, and sanitary goods. With a focus on innovation and quality, Kobayashi Pharmaceutical aims to improve the health and wellness of its customers.
How the Company Makes MoneyKobayashi Pharmaceutical Co., Ltd. generates revenue primarily through the sale of its over-the-counter (OTC) medications, household products, and personal care goods. The company markets a diverse portfolio of products that target everyday health and hygiene needs, such as cold remedies, pain relief medications, and skin care solutions. It also engages in the development and sale of health supplements. The company's revenue model is driven by its strong distribution network, brand recognition, and its ability to consistently launch innovative products that meet consumer demands. Additionally, strategic partnerships and collaborations may also play a role in expanding its market reach and enhancing its product offerings.

Kobayashi Pharmaceutical Co Financial Statement Overview

Summary
Kobayashi Pharmaceutical demonstrates a solid financial position with strong equity and low debt levels. However, challenges exist in revenue growth and profitability, with a declining net profit margin and negative free cash flow needing attention to sustain long-term financial health.
Income Statement
65
Positive
Kobayashi Pharmaceutical has demonstrated stable revenue generation with a moderate gross profit margin of around 53% for 2024. However, there is a notable decline in net profit margin from 11.7% in 2023 to 6.1% in 2024, indicating pressure on profitability. The revenue growth rate was negative at -4.53% from 2023 to 2024, signaling a contraction. EBIT and EBITDA margins are reasonably healthy but show slight declines, reflecting increased operational challenges.
Balance Sheet
82
Very Positive
The company maintains a strong balance sheet with a very low debt-to-equity ratio of 0.004, reflecting minimal leverage risk. The equity ratio remains robust at approximately 80.4%, indicating strong financial stability and shareholder equity. Return on equity (ROE) has decreased to 4.7% in 2024, reflecting reduced net income relative to equity.
Cash Flow
50
Neutral
Free cash flow has turned negative in 2024, a significant drop from the positive free cash flow of 4.79 billion yen in 2023, signaling cash flow challenges. The operating cash flow to net income ratio remains positive, indicating that operating activities are still generating sufficient cash relative to net income, but free cash flow to net income ratio is negative, highlighting concerns over capital expenditures.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue165.60B173.46B166.26B155.25B150.51B
Gross Profit87.60B96.38B92.33B88.77B85.27B
EBITDA32.73B33.65B31.86B30.79B29.91B
Net Income10.07B20.34B20.02B19.71B19.20B
Balance Sheet
Total Assets265.37B267.47B255.83B252.55B238.37B
Cash, Cash Equivalents and Short-Term Investments65.75B79.84B104.53B109.05B94.34B
Total Debt846.00M987.00M792.00M630.00M688.00M
Total Liabilities51.90B62.66B57.93B56.95B55.78B
Stockholders Equity213.47B204.82B197.90B195.60B182.58B
Cash Flow
Free Cash Flow-14.81B4.79B15.69B18.23B19.84B
Operating Cash Flow11.25B18.36B31.91B22.42B23.99B
Investing Cash Flow-18.41B-19.58B-14.31B7.99B-12.66B
Financing Cash Flow-7.77B-19.46B-20.76B-10.38B-6.02B

Kobayashi Pharmaceutical Co Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5348.00
Price Trends
50DMA
5295.63
Positive
100DMA
5377.93
Negative
200DMA
5530.68
Negative
Market Momentum
MACD
-16.66
Negative
RSI
56.27
Neutral
STOCH
93.03
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4967, the sentiment is Positive. The current price of 5348 is above the 20-day moving average (MA) of 5258.60, above the 50-day MA of 5295.63, and below the 200-day MA of 5530.68, indicating a neutral trend. The MACD of -16.66 indicates Negative momentum. The RSI at 56.27 is Neutral, neither overbought nor oversold. The STOCH value of 93.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4967.

Kobayashi Pharmaceutical Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
¥492.18B15.5812.05%1.70%13.95%0.37%
73
Outperform
¥265.93B11.657.98%2.46%3.14%11.57%
69
Neutral
$282.84B37.874.49%4.07%-0.74%-25.66%
65
Neutral
¥355.15B11.37-2.99%2.48%11.78%-10.17%
63
Neutral
$330.49B56.422.08%2.42%4.63%-60.17%
61
Neutral
¥396.62B37.105.17%1.93%-8.36%-38.35%
59
Neutral
$397.87B18.697.58%1.98%2.30%33.87%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4967
Kobayashi Pharmaceutical Co
5,348.00
-587.83
-9.90%
JP:8283
Paltac
4,269.00
-122.33
-2.79%
JP:4527
Rohto Pharmaceutical Co
2,120.00
-1,333.35
-38.61%
JP:4927
Pola Orbis Holdings
1,279.00
-74.82
-5.53%
JP:4922
Kose
5,701.00
-4,022.60
-41.37%
JP:4912
Lion
1,466.00
197.51
15.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025